AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology ...

Johnson Winter Slattery (JWS) has assisted three of the lead investors in AdvanCell’s US$112m Series C financing effort.

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

Brisbane-based AdvanCell raised $178 million in one of the biggest funding rounds of 2025 so far. It's good news for an ...

On February 10, the company announced a collaboration with AdvanCell to advance cancer treatment through targeted alpha therapies. By combining Eli Lilly and Company’s (NYSE:LLY) expertise in ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of ...

Other companies are looking at lead-212 RLTs, meanwhile, including ARTBIO and POINT Biopharma/AdvanCell, but Orano Med is thought to be in the lead in the category. Sanofi's chief executive Paul ...

BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on ...

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a ...